Poster presentations at ERS Milan 2023 International Congress

Two posters, presented together with collaborators from Kings College, London will showcase the latest research on the lead asset EP395 in chronic respiratory diseases.

The first poster describes the effects of EP395 on induced inflammatory cell extravasation in situ. These data provide valuable insight into the compound's ability to affect endothelial barrier function and inhibit inflammatory cell recruitment into surrounding tissues. The second poster presentation outlines the in vivo inflammation resolving effect of EP395, particularly its role in host-microbe interactions, and its ability to alleviate inflammation and inhibit vascular permeability.

A third poster, in collaboration with the University of Iceland, will also present ongoing biomarker and mechanism of action work. This study investigates the cellular and molecular changes macrolide antibiotics have on bronchial epithelial cells, outside of their antimicrobial action.

If you would like to meet the presenters and find out more about this research, details are below. The EpiEndo team will also be attending the conference, if you would like to meet, please get in touch.

Session 68: From bench to bedside: translational studies in airway diseases
Abstract PA599: EP395 effect on cell diapedesis measured by intravital microscopy
Date: 10/09/2023, Time: 08:00 - 09:30, Location: PS-6 in poster area.

Session 450: Increasing understanding of host-microbe interactions in lung diseases
Abstract PA4680: In vivo inflammation resolving effect of EP395
Date: 12/09/2023, Time: 12:30 - 14:00, Location: PS-5 in poster area.

Session 296: Towards the identification of new biomarkers in pulmonary diseases
Abstract PA2965: Comparative analysis of macrolide antibiotics effects on bronchial epithelial cell differentiation in vitro
Date: 11/09/2023, Time: 12:30 – 14:00, Location: PS-4 in poster area.

Contact:

EpiEndo Pharmaceuticals:
Maria Bech, CEO
+354 454 0090­­­

Instinctif Partners (media relations):
Rozi Morris / Batoul Ali
+44 20 7457 2020
epiendo@instinctif.com

About EpiEndo Pharmaceuticals (www.epiendo.com)

EpiEndo is a clinical-stage biopharmaceutical company with a unique approach to inflammatory disorders that focuses on the enhancement of epithelial barrier integrity to reduce disease-causing inflammation.

Epithelial cells are a key part of the barrier that makes up human lung tissue and other organs such as the gut and skin. A breakdown of this barrier is implicated in several chronic inflammatory diseases.

EpiEndo’s new class of orally available macrolide, with reduced AMR effect, known as a ‘Barriolide™’, shows promise as a first-in-class therapeutic for chronic respiratory diseases as well as other inflammatory indications. EpiEndo’s lead asset, EP395, is the first Barriolide™ to enter into Phase 2 clinical trials, for chronic obstructive pulmonary disease (COPD).

EP395, aims to be the first on-market oral, barrier-enhancing and anti-inflammatory drug, which has the potential to be a unique and impactful treatment option for COPD patients. According to the WHO, COPD is the third leading cause of death globally, and the global economic burden of COPD projected to cost $4.8 trillion by 2030.